Press Release: Novartis: FDA approves Pluvicto -2-

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

*Global incidence includes the United States, China, Japan, France, Germany, Italy, Spain and the United Kingdom.

References

1. Novartis data on file.

2. Armstrong AJ, et al. ARCHES: A Randomized, Phase III Study of Androgen

Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic

Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 Nov

10;37(32):2974-2986.

3. Verry C, Vincendeau S, Massetti M, et al. Pattern of clinical progression

until metastatic castration-resistant prostate cancer: an epidemiological

study from the European Prostate Cancer Registry. Target Oncol.

2022;17(4):441-451.

4. Wenzel M, Siech C, Hoeh B, et al. Contemporary treatment patterns and

oncological outcomes of metastatic hormone-sensitive prostate cancer and

first- to sixth- line metastatic castration-resistant prostate cancer

patients. Eur Urol Open Sci. 2024;66:46-54.

5. Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world

treatment patterns and overall survival among men with Metastatic

Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare

population. Prostate Cancer Prostatic Dis. 2024;27(2):327-333.

6. Holmstrom S, Naidoo S, Turnbull J, et al. Symptoms and impacts in

metastatic castration-resistant prostate cancer: qualitative findings

from patient and physician interviews. Patient. 2019;12(1):57-67.

7. Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific

membrane antigen (PSMA) on biopsies is an independent risk stratifier of

prostate cancer patients at time of initial diagnosis. Front Oncol.

2018;8:623.

8. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane

antigen expression in prostatic intraepithelial neoplasia and

adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256-2261.

9. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is

associated with early PSA recurrence in surgically treated prostate

cancer. Prostate. 2011;71(3):281-288.

10. Hope TA, Aggarwal R, Chee B, et al. Impact of 68Ga-PSMA-11 PET on

management in patients with biochemically recurrent prostate cancer. J

Nucl Med. 2017;58(12):1956-1961.

11. Pomykala KL, Czernin J, Grogan TR, et al. Total-body 68Ga-PSMA-11 PET/CT

for bone metastasis detection in prostate cancer patients: potential

impact on bone scan guidelines. J Nucl Med. 2020;61(3):405-411.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41

61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

July 31, 2026 16:25 ET (20:25 GMT)